MIRNA THERAPEUTICS, INC. 2008 LONG TERM INCENTIVE PLAN STOCK OPTION AGREEMENTStock Option Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement is made and entered into as of the Date of Grant set forth in the Notice of Grant of Stock Option (“Notice of Grant”) by and between Mirna therapeutics, Inc., a Delaware corporation (the “Company”), and you:
AMENDMENT No. 1 to LICENSE AGREEMENTLicense Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 to LICENSE AGREEMENT (this “Amendment”) is made and entered into effective as of December 27, 2013 (the “Amendment Effective Date”), by and between Mirna Therapeutics, Inc., a Delaware corporation with offices at 2150 Woodward Street, Suite 100, Austin, Texas 78744 (“MirnaRx”), and Marina Biotech, Inc., a Delaware corporation with offices at 3830 Monte Villa Parkway, Bothell, Washington 98021 (“Marina Bio”).
LICENSE AGREEMENTLicense Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of December 22, 2011 (the “Effective Date”) by and between MIRNA THERAPEUTICS, INC., a Delaware corporation with a place of business at 2150 Woodward Street, Suite 100, Austin, Texas 78744 (“MirnaRx”), and MARINA BIOTECH, INC., a Delaware corporation with a place of business at 3830 Monte Villa Parkway, Bothell, Washington 98021 USA (“Marina Bio”). Marina Bio and MirnaRx are sometimes referred to herein individually as a “Party”, and collectively as the “Parties.”
AMENDED AND RESTATED AGREEMENTAmended and Restated Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDED AND RESTATED AGREEMENT (the “Agreement”) by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut and located in New Haven, Connecticut (“YALE”), and Mirna Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and with principal offices located in Austin, Texas (“LICENSEE”) is effective as of the date of final signature below (“EFFECTIVE DATE”).
MIRNA THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of this 22nd day of October, 2012, by and among MIRNA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the persons and entities listed on Exhibit A hereto (the “Investors” and each individually an “Investor”).
ContractLicense Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CANCER PREVENTION & RESEARCH INSTITUTE OF TEXASCancer Research Grant Contract • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Executive Director, and Mirna Therapeutics, Inc., hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
MIRNA THERAPEUTICS, INC. 2150 Woodward St. #100 Austin, Texas 78744 NOTICE OF GRANT OF STOCK OPTIONMirna Therapeutics, Inc. • April 4th, 2014 • Pharmaceutical preparations
CROSS LICENSE AGREEMENTCross License Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Cross License Agreement (this “Agreement”) is made as of the Effective Date (as such term is defined below) by and between Asuragen, Inc., a Delaware corporation with its principal offices at 2150 Woodward St., Austin, Texas 78744 (“Asuragen”) and Mirna Therapeutics, Inc., a Delaware corporation with an office at 2150 Woodward Street, Austin, Texas 78744 (“Mirna”); (each of Asuragen and Mirna is referred to herein as “Party” and together as the “Parties”).
FIRST AMENDMENT TO THE CROSS LICENSE AGREEMENTLicense Agreement • April 4th, 2014 • Mirna Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to the Cross License Agreement (the “First Amendment”) is by and between Mirna Therapeutics, Inc. (“Mirna”), a Delaware corporation with a principal business address at 2150 Woodward St., Suite 100, Austin, Texas 78744, and Asuragen, Inc., a Delaware corporation, with a principal business address at 2150 Woodward Street, Austin, Texas 78744 (“Asuragen”), and is effective as of September 28, 2012 (the “First Amendment Effective Date”). All capitalized terms not defined in this First Amendment shall have the meanings given to them in the Cross License Agreement (including Exhibits thereto) entered into by and between Mirna and Asuragen, effective as of November 3, 2009 (the “Agreement”).
ContractMirna Therapeutics, Inc. • April 4th, 2014 • Pharmaceutical preparations • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractMirna Therapeutics, Inc. • April 4th, 2014 • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
